Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Gastritis II: Pathophysiology

Gastritis II: Pathophysiology

The pathophysiology of gastritis begins with the colonization of the stomach lining by Helicobacter pylori (H. pylori). This bacterium spreads mainly via the oral-oral route through saliva or shared utensils, and can also be transmitted in overcrowded or unhygienic environments through contaminated water, despite its brief survival outside the body.ColonizationOnce ingested, H. pylori enters the stomach and begins colonization by navigating through the mucus layer lining the stomach wall. It...

Gastritis-I: Introduction and Types

Gastritis-I: Introduction and Types

Gastritis, defined by the inflammation or irritation of the stomach lining or gastric mucosa, manifests in several distinct forms: acute, chronic, reactive, and a specific subtype known as autoimmune metaplastic atrophic gastritis.
Acute gastritis presents as a sudden inflammation triggered by various stressors to the stomach lining, such as exposure to corrosive agents, local irritants like aspirin and other NSAIDs, alcohol consumption, radiation therapy, physical trauma, severe burns, sepsis,...

Peptic Ulcer

Peptic Ulcer

Peptic ulcers are erosive lesions of the gastric or duodenal lining, most commonly caused by Helicobacter pylori infection. This Gram-negative, helical bacterium has adapted to survive the stomach’s acidic environment by producing urease, which converts urea into ammonia and carbon dioxide. The ammonia neutralizes gastric acid in the bacterium’s immediate environment, allowing colonization of the gastric mucosa. H. pylori attaches to mucus-secreting epithelial cells, penetrates the mucus...

Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies

Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies

Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.

Gastritis III: Clinical Manifestations and Management

Gastritis III: Clinical Manifestations and Management

The clinical manifestations of gastritis can vary depending on the cause and type of gastritis, but some common symptoms may include the following.
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...

Peptic Ulcer Disease I: Introduction

Peptic Ulcer Disease I: Introduction

Peptic Ulcer Disease (PUD) is characterized by mucosal excavation in the esophagus, stomach, pylorus, or duodenum. It can manifest as acute or chronic based on the extent and duration of mucosal involvement.
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Management of older adults with colorectal cancer - The state-of-the-art in 2026.

Journal of geriatric oncology·2026

Same author

Biomarker analysis from patients with metastatic PDAC treated with TGFβ antibody, NIS793, plus abraxane+gemcitabine vs. abraxane+gemcitabine alone in a phase II, open label, randomized study.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Same author

AI-driven volumetric approach for automatic chemotherapy response assessment in colorectal liver metastases.

European radiology·2026

Same author

Management of colorectal cancer in older adults: an expert panel recommendation to guide daily clinical practice.

The lancet. Gastroenterology & hepatology·2026

Same author

FRUQUITAS trial: Study design of an ENGIC intergroup randomized phase III of trifluridine/tipiracil +/- fruquintinib in pre-treated metastatic gastro-oesophageal adenocarcinoma.

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·2026

Same author

Postoperative Hepatic Arterial Infusion With Oxaliplatin After Surgery of Four or More Colorectal Liver Metastases: A Randomized Phase II Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Same journal

[Prolonged fever].

La Revue du praticien·2026

Same journal

[Lower gastrointestinal bleeding].

La Revue du praticien·2026

Same journal

[Management of antiplatelet agents and oral anticoagulants in cases of gastrointestinal bleeding].

La Revue du praticien·2026

Same journal

[A history of child abuse intervention in the West].

La Revue du praticien·2026

Same journal

[Agranulocytose médicamenteuse].

La Revue du praticien·2026

Same journal

[Patient education in heart failure].

La Revue du praticien·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 28, 2026

Establishment and Evaluation of a Risk Prediction Model for Pathological Escalation of Gastric Low-Grade Intraepithelial Neoplasia

Establishment and Evaluation of a Risk Prediction Model for Pathological Escalation of Gastric Low-Grade Intraepithelial Neoplasia

Published on: February 16, 2024

[Premalignant gastric lesions (except lymphomas)].

Céline Lobry¹, Thomas Aparicio, Thierry Vallot

¹Service d'hépato-gastroentérologie, CHU Bichat-Claude-Bernard, Université Paris-Diderot Paris-7 75877 Paris Cedex 18, France.

La Revue Du Praticien

|October 18, 2008

Summary

This summary is machine-generated.

Several gastric conditions increase cancer risk, including atrophic gastritis and intestinal metaplasia. While Helicobacter pylori plays a role, its eradication efficacy for precancerous lesions remains uncertain, especially in low-incidence regions.

Related Experiment Videos

Last Updated: Jun 28, 2026

Establishment and Evaluation of a Risk Prediction Model for Pathological Escalation of Gastric Low-Grade Intraepithelial Neoplasia

Establishment and Evaluation of a Risk Prediction Model for Pathological Escalation of Gastric Low-Grade Intraepithelial Neoplasia

Published on: February 16, 2024

Area of Science:

Gastroenterology and Oncology
Pathology of the Digestive System

Background:

Atrophic gastritis, intestinal metaplasia, and gastric ulcers are recognized precursors to gastric carcinoma.
Autoimmune conditions and post-gastrectomy changes also elevate gastric cancer risk.
Helicobacter pylori infection is a significant factor in gastric carcinogenesis.

Purpose of the Study:

To review conditions associated with increased gastric cancer risk.
To evaluate the role of H. pylori eradication in reversing precancerous gastric lesions.
To discuss the consensus on endoscopic surveillance for premalignant gastric conditions.

Main Methods:

Literature review of studies on gastric precancerous lesions and gastric carcinoma.
Analysis of the impact of H. pylori eradication on premalignant conditions.
Examination of current guidelines for endoscopic surveillance in low-incidence gastric cancer regions.

Main Results:

Conditions like atrophic gastritis, intestinal metaplasia, and gastric ulcers are linked to higher gastric cancer incidence.
The benefit of H. pylori eradication in reverting these precancerous changes is not definitively established.
Consensus on endoscopic surveillance is lacking for most premalignant conditions, except for dysplasia, particularly in low-risk populations.

Conclusions:

Multiple gastric conditions confer an increased risk of developing gastric carcinoma.
The therapeutic value of H. pylori eradication for precancerous lesions requires further investigation.
Standardized endoscopic surveillance protocols for premalignant gastric conditions are needed, especially in low-incidence areas.